[Evidence data and importance of public health of the new antipsychotics].
Launois
R
R
Economiste, Université Paris XIII.
D000553:Ambulatory Care / Q000191:economics; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics; D016527:Drug Costs / Q000706:statistics & numerical data*; D019317:Evidence-Based Medicine / Q000191:economics; D005602:France; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007902:Length of Stay / Q000191:economics; D011057:Politics; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000191:economics; D011634:Public Health; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics
D014150:Antipsychotic Agents